Global Optical Genome Mapping Market 2025-2035

Description

List of Tables

Global Optical Genome Mapping Market Size, Share & Trends Analysis Report By Offerings (Consumables, Instruments, Services, and Software), By Application (Genome Assembly, Structural Variation Detection, Microbial Strain Typing, Haplotype Phasing, and Others (Improving De Novo Plant Genome Assemblies, Identifying Genetic Abnormalities, Diagnosing Non-Hematological Cancers), And By End Users (Research & Academic Institutions, Biotechnology & Pharmaceutical Companies, Clinical Laboratories And Others (CRO)), Forecast Period (2025-2035)

Industry Overview

Optical genome mapping market, estimated at $132 million in 2024, is projected to grow to $1.5 billion with a CAGR of 23.9% during the forecast period (2025-2035). Optical genome mapping used in the field of molecular cytogenetics has the potential to replace conventional testing methodologies in clinical diagnostics. The growing adoption of cytogenetic/molecular genetics technologies with improved standard diagnostics is the key factor supporting the growth of the market globally. Dubbed 'New Generation Cytogenetics', optical genome mapping, when compared to conventional diagnostic techniques, offers better resolution and can detect a wider range of genetic abnormalities. Hence, the market players are also focusing on introducing next-generation genetic testing tools that further bolster the market growth. For instance, in July 2023, the Centre for Cellular & Molecular Biology (CCMB) in Hyderabad, India, launched an innovative high-end next-generation genetic testing tool called 'Optical Genome Mapping' (OGM) that may discover genomic anomalies causing a variety of hereditary diseases in humans.

Market Dynamics

Increasing Adoption in Clinical Diagnostics

OGM is revolutionizing clinical genomics by enabling high-resolution detection of structural variants (SVs) associated with cancers, neurodevelopmental disorders, and rare diseases. For example, as per the Centers for Disease Control and Prevention (CDC) report, 1 in every 33 babies is born in the United States each year. Birth defects are the leading cause of infant deaths, accounting for 20% of all infant deaths. This can be minimized by improving OGM technology by sequencing DNA. For instance, OGM platforms like Bionano Genomics' Saphyr system are FDA-registered for clinical use, offering faster and more accurate SVs analysis compared to traditional cytogenetic methods. Hospitals and labs are increasingly adopting OGM to replace outdated techniques.

Rising Demand for OGM due to Increasing Disease Burden

Simultaneously, with the increasing number of cancer cases all over the world, which caused nearly 10 million deaths globally in 2020, OGM's role in identifying complex genomic alterations is critical for early diagnosis and personalized therapies. Moreover, OGM has been validated as a laboratory-developed test (LDT) under CAP/CLIA guidelines, demonstrating 100% concordance with standard methods in detecting SVs for hematological malignancies. Increasing demand for precise, high-resolution genomic analysis and OGM systems enables researchers and clinicians to visualize entire genomic structures, detect large-scale structural variants, and gain insights into complex genetic disorders, further accelerating the demand for advanced OGM.

Market Segmentation

Based on the offerings, the market is segmented into consumables, instruments, services, and software).
Based on the application, the market is segmented into genome assembly, structural variation detection, microbial strain typing, haplotype phasing, and others (improving de novo plant genome assemblies, identifying genetic abnormalities, and diagnosing non-hematological cancers).
Based on the end users, the market is segmented into research & academic institutions, biotechnology & pharmaceutical companies, clinical laboratories, and others (CRO).

The Research and Academic Institutions Sub-Segment is Anticipated to Hold a Considerable Share of the Global Optical Genome Mapping Market

The research & academic Institutions sub-segment is expected to hold a considerable share of the global optical genome mapping market among the end users. The segmental growth is attributed to the growing influence of optical mapping in recent decades, to illustrate its importance in genomic research. Research and academic Institutions provide researchers with a unique data set that will help them assess the true potential of genetics-based, precision medicine approaches to guide everyday patient care and generate new insights to guide the discovery and development of potential new therapies. For instance, in August 2022, Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC), part of the industry-leading, New York-based biotechnology company Regeneron.

Regional Outlook

The global optical genome mapping market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America is Expected to Hold the Largest Market Share

The North American region is expected to witness significant growth opportunities for the market. Rising advanced healthcare infrastructure and significant R&D investments. For instance, per National Human Genome Research Institute (NHGRI) is awarding $5.4 million in first-year funding to establish a new program that supports the integration of genomics into learning health systems. Additionally, the new Genomics-enabled Learning Health System (gLHS) Network aims to identify and advance approaches for integrating genomic information into existing learning health systems. Furthermore, the National Institutes of Health (NIH) has partnered with the U.S. National Science Foundation (NSF) to provide approximately $15.4 million over three years for research into the structures, functions, and interactions of ribonucleic acid (RNA), as well as the creation of RNA-based technologies.

Research and Development Efforts in China

Chinese research institutes are implementing optical genome mapping in various research areas. For example, in January 2025, Bionano Genomics, Inc. announced the publication of a case study from the Shenzhen Maternity and Child Healthcare Hospital, China, demonstrating the application of optical genome mapping (OGM) in a protocol for preimplantation genetic testing for structural rearrangements (PGT-SR). In-vitro fertilization (IVF) and the PGT-SR protocol, which included OGM, led to the selection of the presumed most viable embryos, resulting in a viable pregnancy and the birth of a healthy baby to a couple experiencing years of recurrent pregnancy loss (RPL).

Market Players Outlook

The major companies operating in the global optical genome mapping market include Bionano Genomics, Inc., Nabsys, Inc., Illumina, Inc., and Thermo Fisher Scientific, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2024, NewBiologix SA, a company, announced the launch of its next-generation sequencing (NGS) and optical mapping platform, a novel suite of technologies combined to offer comprehensive genomic analysis services to the biopharmaceutical industry. This platform integrates the latest advancements in sequencing and genomic mapping technologies, combining the strengths of industry leaders such as Illumina, PacBio, Nanopore, and Bionano.
In January 2024, Bionano Genomics, Inc. announced the full commercial release of the Stratys system, the Company's system for high-throughput optical genome mapping (OGM). Bionano's Stratys system offers increased flexibility and throughput capabilities to address the needs of mid and high-volume users. It is compatible and has a potential sample-to-answer time of 3 days for hematological samples interrogated across the whole genome at high sensitivity to rare variants.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global optical genome mapping market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027818

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Optical Genome Mapping Market Sales Analysis - Offerings | Application | End-Users ($ Million)
Optical Genome Mapping Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Optical Genome Mapping Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Optical Genome Mapping Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Optical Genome Mapping Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Optical Genome Mapping Market Revenue and Share by Manufacturers
Optical Genome Mapping Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Bionano Genomics, Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Nabsys, Inc.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Illumina, Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Thermo Fisher Scientific, Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Optical Genome Mapping Market Sales Analysis By Offerings ($ Million)

5.1. Consumables
5.2. Instruments
5.3. Services
5.4. Software

6. Global Optical Genome Mapping Market Sales Analysis By Application ($ Million)

6.1. Genome Assembly
6.2. Structural Variation Detection
6.3. Microbial Strain Typing
6.4. Haplotype Phasing
6.5. Others (Improving De Novo Plant Genome Assemblies, Identifying Genetic Abnormalities, Diagnosing Non-Haematological Cancers)

7. Global Optical Genome Mapping Market Sales Analysis By End-Users ($ Million)

7.1. Research & Academic Institutions
7.2. Biotechnology & Pharmaceutical Companies
7.3. Clinical Laboratories
7.4. Others (CRO)

8. Regional Analysis

8.1. North American Optical Genome Mapping Market Sales Analysis - Offerings | Application | End-Users ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Optical Genome Mapping Market Sales Analysis - Offerings | Application | End-Users ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Optical Genome Mapping Market Sales Analysis - Offerings | Application | End-Users ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Optical Genome Mapping Market Sales Analysis - Offerings | Application | End-Users ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Agilent Technologies, Inc.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Bionano Genomics, Inc.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Beckman Coulter, Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bio-Rad Laboratories, Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Illumina, Inc.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Nabsys, Inc.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Novogene Co., Ltd.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Pacific Biosciences of California, Inc.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Roche Sequencing Solutions, Inc. (Hoffmann-La Roche Ltd)
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. SOPHiA GENETICS
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Thermo Fisher Scientific, Inc.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies